Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash
Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Purpose
Cetuximab inhibits the epidermal growth factor receptor (EGFR), and papulopustular eruptions is a frequent side effect. Vitamin K3 (menadione) has preclinically shown to be a potential activator of the EGFR by phosphorylating the receptor (pEGFR). The present randomised study investigated the effect of a vitamin K3 cream on cetuximab-ind...
Alternative Titles
Full title
Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1902403742
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1902403742
Other Identifiers
ISSN
0941-4355
E-ISSN
1433-7339
DOI
10.1007/s00520-017-3623-x
